CG Oncology, Inc. CGON
- Headquarters
- Dallas, TX
- CEO
- Arthur Kuan
- Next results
- around Feb 26, 2027
What changed
13 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 27, 2026 against Mar 28, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 8 checks found nothing to note
-
Critical audit matters changedNew this year: Accrued Clinical Expenses (“During 2025, the Company incurred $116.6 million of research and development expenses and accrued $13.9 million for external research and development expenses as of December 31, 2025, which includes clinical expenses. As described in Notes 2 and 6 to the consolidated financial statements, clinical e”)
-
Cash from operations −$132.3M vs net income −$161.0M (FY ending Dec 31, 2025)
7 more checks with nothing to note
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
13 paragraphs in Risk Factors that were not in the 10-K filed Mar 28, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Mar 28, 2025 10-K, ITEM 1A
Since its enactment, there have been executive, judicial and Congressional challenges and amendments to certain aspects of the ACA. For example, on July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced…
-
Item 1A · new paragraph · not in the 10-K filed Mar 28, 2025 10-K, ITEM 1A
We acquired a controlling interest in Biovire, Inc., a contract manufacturing organization that provides our clinical supply and, if any of our product candidates are approved, we expect will provide our commercial supply of cretostimogene. We do not have experience operating a contract manufacturing organization, which organizations…
-
Item 1A · new paragraph · not in the 10-K filed Mar 28, 2025 10-K, ITEM 1A
We operate in a global economy, which includes utilizing third-party suppliers in several countries outside the United States. There is inherent risk, based on the complex relationships among the U.S. and the countries in which we conduct our business, that political, diplomatic, and national security factors can lead to global trade…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 3 fiscal years · 10-K XBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $204K | $1.1M | $4.0M |
| Net income | −$48.6M | −$88.0M | −$161.0M |
| Operating cash flow | −$45.7M | −$78.7M | −$132.3M |
| Free cash flow | −$78.9M | −$132.5M |
Revenue, FY2023 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$4.0M ▲ 254.7% in FY2025−$161.0M in FY2025
Recent filings
2 filings in the last 30 days · SEC EDGAR
-
8-KNov 6, 2026Quarterly results 8-K item 2.02
-
10-QNov 6, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
CG Oncology, Inc., Dallas, TX · from the 10-K filed Feb 27, 2026
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec (cretostimogene), an investigational oncolytic immunotherapy with a dual mechanism of action designed both to eliminate cancer cells directly by selective replication and indirectly by activating an anti-tumor immune response, as a potential backbone therapy in a broad range of patients afflicted with bladder cancer. Cretostimogene is currently in clinical development for the treatment of patients with high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), which potentially represents up to 150,000 addressable patients.
- Headquarters
- Dallas, TX
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 6, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Mar 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CGON/export.csv") into a cell.